FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2013336475> ?p ?o ?g. }

• W2013336475 endingPage "1710" @default.
• W2013336475 startingPage "1704" @default.
• W2013336475 abstract "The polycomb group proteins have recently captured the attention of cancer biologists. enhancer of zeste homologue 2 (EZH2) and B lymphoma Mo-MLV insertion region 1 homolog (BMI-1) are the best-characterized polycomb group proteins; their deregulation contributes to the development of many malignancies including gastric cancers. H3 trimethylation at lysine 27 and DNA methylase DNA methyltransferase 3B proteins are associated with the recruitment of polycomb group proteins. Overexpression of polycomb group proteins is associated with poor prognoses in some types of cancers but with favorable prognoses in others. In the present study, we investigated the expression of the polycomb group proteins EZH2 and BMI-1 and the associated proteins H3 trimethylation at lysine 27 and DNA methyltransferase 3B in advanced gastric cancers. Based on immunohistochemical detection, we evaluated the clinical relevance of these proteins in 178 cases of advanced gastric cancers that were managed with radical surgery and adjuvant systemic chemotherapy. BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were overexpressed in the nuclei of gastric carcinoma compared with adjacent nonneoplastic gastric parenchyma. The high-level expression of BMI-1, enhancer of zeste homologue 2, H3 trimethylation at lysine 27, and DNA methyltransferase 3B proteins were frequently noted in advanced gastric cancer tissues (70.8%, 92.1%, 58.4%, and 64.6% of cases, respectively) and well intercorrelated in expression (P < .05). The expression level of BMI-1, enhancer of zeste homologue 2, and DNA methyltransferase 3B showed correlation with sex, gross type, and histologic type of the tumor among clinicopathologic variables. In terms of patient survival, low-level expression of enhancer of zeste homologue 2 was associated with cancer-related death (P = .018) and shorter overall survival (P = .005). Low-level expression of enhancer of zeste homologue 2 may represent a negative prognostic marker (P = .005) and indicate high risk in patients with advanced gastric cancer after surgery and adjuvant chemotherapy." @default.
• W2013336475 created "2016-06-24" @default.
• W2013336475 creator A5002834964 @default.
• W2013336475 creator A5016116108 @default.
• W2013336475 creator A5021363331 @default.
• W2013336475 creator A5032084420 @default.
• W2013336475 creator A5046537693 @default.
• W2013336475 creator A5067849263 @default.
• W2013336475 date "2012-10-01" @default.
• W2013336475 modified "2023-10-05" @default.
• W2013336475 title "Immunohistochemical analysis of polycomb group protein expression in advanced gastric cancer" @default.
• W2013336475 cites W1964456085 @default.
• W2013336475 cites W1974904178 @default.
• W2013336475 cites W1986072799 @default.
• W2013336475 cites W1989636291 @default.
• W2013336475 cites W1996487270 @default.
• W2013336475 cites W2004380823 @default.
• W2013336475 cites W2008207367 @default.
• W2013336475 cites W2021963931 @default.
• W2013336475 cites W2029634407 @default.
• W2013336475 cites W2039948198 @default.
• W2013336475 cites W2041022120 @default.
• W2013336475 cites W2050419281 @default.
• W2013336475 cites W2062586342 @default.
• W2013336475 cites W2067457920 @default.
• W2013336475 cites W2071742054 @default.
• W2013336475 cites W2079298594 @default.
• W2013336475 cites W2087663062 @default.
• W2013336475 cites W2096590516 @default.
• W2013336475 cites W2101139969 @default.
• W2013336475 cites W2105178859 @default.
• W2013336475 cites W2109388391 @default.
• W2013336475 cites W2115992310 @default.
• W2013336475 cites W2121737942 @default.
• W2013336475 cites W2128064256 @default.
• W2013336475 cites W2151163394 @default.
• W2013336475 cites W2154128690 @default.
• W2013336475 cites W2159815377 @default.
• W2013336475 doi "https://doi.org/10.1016/j.humpath.2011.12.019" @default.
• W2013336475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22520951" @default.
• W2013336475 hasPublicationYear "2012" @default.
• W2013336475 type Work @default.
• W2013336475 sameAs 2013336475 @default.
• W2013336475 citedByCount "19" @default.
• W2013336475 countsByYear W20133364752012 @default.
• W2013336475 countsByYear W20133364752013 @default.
• W2013336475 countsByYear W20133364752014 @default.
• W2013336475 countsByYear W20133364752015 @default.
• W2013336475 countsByYear W20133364752016 @default.
• W2013336475 countsByYear W20133364752017 @default.
• W2013336475 countsByYear W20133364752018 @default.
• W2013336475 countsByYear W20133364752019 @default.
• W2013336475 countsByYear W20133364752021 @default.
• W2013336475 countsByYear W20133364752022 @default.
• W2013336475 countsByYear W20133364752023 @default.
• W2013336475 crossrefType "journal-article" @default.
• W2013336475 hasAuthorship W2013336475A5002834964 @default.
• W2013336475 hasAuthorship W2013336475A5016116108 @default.
• W2013336475 hasAuthorship W2013336475A5021363331 @default.
• W2013336475 hasAuthorship W2013336475A5032084420 @default.
• W2013336475 hasAuthorship W2013336475A5046537693 @default.
• W2013336475 hasAuthorship W2013336475A5067849263 @default.
• W2013336475 hasConcept C104317684 @default.
• W2013336475 hasConcept C111936080 @default.
• W2013336475 hasConcept C121608353 @default.
• W2013336475 hasConcept C150194340 @default.
• W2013336475 hasConcept C153911025 @default.
• W2013336475 hasConcept C158448853 @default.
• W2013336475 hasConcept C203014093 @default.
• W2013336475 hasConcept C204232928 @default.
• W2013336475 hasConcept C2777116130 @default.
• W2013336475 hasConcept C2779979206 @default.
• W2013336475 hasConcept C33288867 @default.
• W2013336475 hasConcept C50171091 @default.
• W2013336475 hasConcept C502942594 @default.
• W2013336475 hasConcept C54355233 @default.
• W2013336475 hasConcept C552990157 @default.
• W2013336475 hasConcept C86803240 @default.
• W2013336475 hasConcept C91965660 @default.
• W2013336475 hasConceptScore W2013336475C104317684 @default.
• W2013336475 hasConceptScore W2013336475C111936080 @default.
• W2013336475 hasConceptScore W2013336475C121608353 @default.
• W2013336475 hasConceptScore W2013336475C150194340 @default.
• W2013336475 hasConceptScore W2013336475C153911025 @default.
• W2013336475 hasConceptScore W2013336475C158448853 @default.
• W2013336475 hasConceptScore W2013336475C203014093 @default.
• W2013336475 hasConceptScore W2013336475C204232928 @default.
• W2013336475 hasConceptScore W2013336475C2777116130 @default.
• W2013336475 hasConceptScore W2013336475C2779979206 @default.
• W2013336475 hasConceptScore W2013336475C33288867 @default.
• W2013336475 hasConceptScore W2013336475C50171091 @default.
• W2013336475 hasConceptScore W2013336475C502942594 @default.
• W2013336475 hasConceptScore W2013336475C54355233 @default.
• W2013336475 hasConceptScore W2013336475C552990157 @default.
• W2013336475 hasConceptScore W2013336475C86803240 @default.
• W2013336475 hasConceptScore W2013336475C91965660 @default.
• W2013336475 hasIssue "10" @default.
• W2013336475 hasLocation W20133364751 @default.

• next